Share with your friends

The New 3rd Board: a boon to the Chinese OTC market

The New 3rd Board: a boon to the Chinese OTC mark...

Our View - Issue VIII, September 2015


Related content

Our View

In this issue of “Our view” we delve into some of the issues regarding how Shanghai’s emerging ‘New 3rd Board’ has been affecting M&A. Points of note include:

  • a fundamental shift in China’s OTC capital markets and how small and mid-sized firms are availing of the various opportunities
  • how Shanghai’s New 3rd Board is emerging as an alternative listing option, creating new challenges for inbound M&A
  • the relatively high index levels being used as a benchmark by some China firms in deal negotiations in respect to valuations.

© 2021 KPMG Huazhen LLP, a People's Republic of China partnership, KPMG Advisory (China) Limited, a limited liability company in China, KPMG, a Macau partnership and KPMG, a Hong Kong partnership, are member firms of the KPMG global organisation of independent member firms affiliated with KPMG International Limited  ("KPMG International"), a private English company limited by guarantee. All rights reserved. The KPMG name and logo are registered trademarks or trademarks of KPMG International.


For more detail about the structure of the KPMG global organisation please visit

Connect with us